Physician profile

Mary E Ciesa

Nurse Practitioner · Akron, OH

NPI 1417971359

$1,263.85

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $183.72 2021-2022
Novo Nordisk INC $143.41 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $121.11 2021-2022
Merck Sharp & Dohme LLC $100.21 2021
Lilly USA, LLC $88.39 2021
Alfasigma USA, INC. $79.70 2021-2022
Biohaven Pharmaceuticals, INC. $69.76 2021
Pfizer INC. $48.57 2021-2022
Astellas Pharma US INC $43.73 2021
Amarin Pharma, INC. $40.98 2021
Amgen INC. $40.96 2021-2022
Biogen, INC. $37.22 2021
Boehringer Ingelheim Pharmaceuticals, INC. $36.84 2021
Biocryst US Sales Co., LLC $35.74 2021
Bayer Healthcare Pharmaceuticals INC. $35.22 2021-2022
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $28.42 2021
Glaxosmithkline, LLC. $27.38 2021
Radius Health, INC. $19.27 2021
Jazz Pharmaceuticals INC. $16.85 2021
Baxter Healthcare $15.88 2022
Seqirus USA INC $14.26 2022
Novartis Pharmaceuticals Corporation $13.62 2022
Sanofi-Aventis U.S. LLC $11.44 2021
Astrazeneca Pharmaceuticals LP $11.17 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mary E Ciesa

$1,263.85

in general payments reported 2019-2025

Years
2021-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/10694209/mary-e-ciesa

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.